<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587480</url>
  </required_header>
  <id_info>
    <org_study_id>Luo-20180624</org_study_id>
    <nct_id>NCT03587480</nct_id>
  </id_info>
  <brief_title>Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy</brief_title>
  <acronym>TELEPHOME</acronym>
  <official_title>Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection(LLDD) Versus Neoadjuvant Chemoradiotherapy(nCRT) Followed by Total Mesorectal Excision Alone on Patients of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis (TELEPHOME).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sixth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sixth Affiliated Hospital, Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis
      are quite different between Japanese guideline (JSCCR) and western countries' guideline
      (NCCN, ESMO). While Japanese scholars advocate total mesorectal excision (TME) plus lateral
      lymph node dissection (LLND), European and American scholars advocate TME alone after
      Neoadjuvant Chemo-radiotherapy (nCRT), without the need of LLND. Accordingly, this clinical
      trial is designed to directly compare the efficacy and safety of these two treatment
      strategies for low rectal cancer with regional lymph node metastasis. It will provide
      high-level clinical evidence for the treatment of low rectal cancer with suspected local
      lymph node metastasis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">May 24, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year disease-free survival</measure>
    <time_frame>From date of operation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Operation day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>Operation day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of sexual dysfunction</measure>
    <time_frame>From the date of operation until the date of complication,assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of urinary dysfunction</measure>
    <time_frame>From the date of operation until the date of complication,assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of defecation dysfunction</measure>
    <time_frame>From the date of operation until the date of complication,assessed up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of Postoperative complications</measure>
    <time_frame>From the date of operation until the date of complication,assessed up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From the date of operation until the date of death,assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year local recurrence rate</measure>
    <time_frame>From date of operation until the date of local-recurrence (up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival</measure>
    <time_frame>From date of operation until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the score of quality of life</measure>
    <time_frame>3 months after operation</time_frame>
    <description>The study investigate the quality of life using the WHOQOL Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Rectal Neoplasm Malignant</condition>
  <arm_group>
    <arm_group_label>TME+LLND group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Total Mesorectal Excision plus Lateral Lymph Node Dissection for low rectal cancer with regional lymph node metastasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TME+nCRT group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Total Mesorectal Excision After Neoadjuvant Chemo-radiotherapy for low rectal cancer with regional lymph node metastasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME+LLND</intervention_name>
    <description>patients in TME+LLND group receive Lateral Lymph Node Dissection (LLND) after Total Mesorectal Excision(TME)</description>
    <arm_group_label>TME+LLND group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME+nCRT</intervention_name>
    <description>patients in TME+nCRT group receive Neoadjuvant Chemo-radiotherapy (nCRT) before Total Mesorectal Excision(TME)</description>
    <arm_group_label>TME+nCRT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed adenocarcinoma(below the peritoneal reflection) Clinical
             stage Ⅲ

          2. Tumor is capable of performing radical recession

          3. No past history of chemotherapy, pelvic radiation of other cancers.

          4. Written informed consent

          5. Lower tumor margin is confirmed below the peritoneal reflection

          6. Clinical state T(1-3)N(1-2)M0 is confirmed by the multiple disciplines team(MDT)
             including surgeons,diagnostic radiologist,radiation oncologist and medical oncologists
             base on MRI and endorectal ultrasound -

        Exclusion Criteria:

          1. Past history of other cancers

          2. Multiple Primary Colorectal Cancers or Familial adenomatous polyposis(FAP)

          3. Combine with inflammatory bowl disease(IBD)

          4. Recurrence tumor or invade other organs

          5. Combine with obstruction,perforation or bleeding which need emergency surgery.

          6. Local tumor invade the external sphincter, levator ani muscle or adjacent organs

          7. Participant join other clinical trials in 4 weeks.

          8. American Society of Anesthesiologists(ASA) ≥Ⅳ and/or Eastern Cooperative Oncology
             Group(ECOG) ≤2

          9. Pregnant or lactating patients

         10. Severity infection before operation

         11. Psychological disorder

         12. Severe dysfunction of organs or other contraindications

         13. Cardiac infarction within six months

         14. Severe pulmonary emphysema and pulmonary fibrosis

         15. Doctor's decision for exclusion

         16. Operative findings:

        Tumor invade other organs Lower tumor margin is above the peritoneal reflection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanxin Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sixth Affiliated Hospital, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanxin Luo</last_name>
    <phone>020-38250745</phone>
    <email>luoyx25@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaoyong Peng</last_name>
    <phone>86-13435613566</phone>
    <email>pengshy9@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Sixth Affiliate Hospital of Sun Yat-Sen University</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanxin Luo, PhD,MD</last_name>
      <phone>86-13826190263</phone>
      <email>luoyx25@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shaoyong Peng, MD</last_name>
      <phone>86-13435613566</phone>
      <email>pengshy9@mail2.sysu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Ito M, Kobayashi A, Fujita S, Mizusawa J, Kanemitsu Y, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Urinary dysfunction after rectal cancer surgery: Results from a randomized trial comparing mesorectal excision with and without lateral lymph node dissection for clinical stage II or III lower rectal cancer (Japan Clinical Oncology Group Study, JCOG0212). Eur J Surg Oncol. 2018 Apr;44(4):463-468. doi: 10.1016/j.ejso.2018.01.015. Epub 2018 Jan 17.</citation>
    <PMID>29428473</PMID>
  </reference>
  <reference>
    <citation>Deng Y, Chi P, Lan P, Wang L, Chen W, Cui L, Chen D, Cao J, Wei H, Peng X, Huang Z, Cai G, Zhao R, Huang Z, Xu L, Zhou H, Wei Y, Zhang H, Zheng J, Huang Y, Zhou Z, Cai Y, Kang L, Huang M, Peng J, Ren D, Wang J. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J Clin Oncol. 2016 Sep 20;34(27):3300-7. doi: 10.1200/JCO.2016.66.6198. Epub 2016 Aug 1.</citation>
    <PMID>27480145</PMID>
  </reference>
  <reference>
    <citation>Qin Q, Ma T, Deng Y, Zheng J, Zhou Z, Wang H, Wang L, Wang J. Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. Dis Colon Rectum. 2016 Oct;59(10):934-42. doi: 10.1097/DCR.0000000000000665.</citation>
    <PMID>27602924</PMID>
  </reference>
  <reference>
    <citation>Huang M, Lin J, Yu X, Chen S, Kang L, Deng Y, Zheng J, Luo Y, Wang L, Lan P, Wang J. Erectile and urinary function in men with rectal cancer treated by neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy alone: a randomized trial report. Int J Colorectal Dis. 2016 Jul;31(7):1349-57. doi: 10.1007/s00384-016-2605-7. Epub 2016 Jun 6.</citation>
    <PMID>27270480</PMID>
  </reference>
  <results_reference>
    <citation>Shinagawa T, Tanaka T, Nozawa H, Emoto S, Murono K, Kaneko M, Sasaki K, Otani K, Nishikawa T, Hata K, Kawai K, Watanabe T. Comparison of the guidelines for colorectal cancer in Japan, the USA and Europe. Ann Gastroenterol Surg. 2017 Dec 19;2(1):6-12. doi: 10.1002/ags3.12047. eCollection 2018 Jan. Review.</citation>
    <PMID>29863118</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujita S, Akasu T, Mizusawa J, Saito N, Kinugasa Y, Kanemitsu Y, Ohue M, Fujii S, Shiozawa M, Yamaguchi T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trial. Lancet Oncol. 2012 Jun;13(6):616-21. doi: 10.1016/S1470-2045(12)70158-4. Epub 2012 May 15.</citation>
    <PMID>22591948</PMID>
  </results_reference>
  <results_reference>
    <citation>Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K, Ohue M, Ota M, Akazai Y, Shiozawa M, Yamaguchi T, Bandou H, Katsumata K, Murata K, Akagi Y, Takiguchi N, Saida Y, Nakamura K, Fukuda H, Akasu T, Moriya Y; Colorectal Cancer Study Group of Japan Clinical Oncology Group. Mesorectal Excision With or Without Lateral Lymph Node Dissection for Clinical Stage II/III Lower Rectal Cancer (JCOG0212): A Multicenter, Randomized Controlled, Noninferiority Trial. Ann Surg. 2017 Aug;266(2):201-207. doi: 10.1097/SLA.0000000000002212.</citation>
    <PMID>28288057</PMID>
  </results_reference>
  <results_reference>
    <citation>Nagawa H, Muto T, Sunouchi K, Higuchi Y, Tsurita G, Watanabe T, Sawada T. Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy. Dis Colon Rectum. 2001 Sep;44(9):1274-80.</citation>
    <PMID>11584199</PMID>
  </results_reference>
  <results_reference>
    <citation>Ogura A, Akiyoshi T, Nagasaki T, Konishi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Kuroyanagi H. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy. World J Surg. 2017 Mar;41(3):868-875. doi: 10.1007/s00268-016-3762-0.</citation>
    <PMID>27730352</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Low rectal cancer</keyword>
  <keyword>Total Mesorectal Excision (TME)</keyword>
  <keyword>neoadjuvant Chemo-radiotherapy (nCRT)</keyword>
  <keyword>lateral lymph node dissection (LLND)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

